Humanized PDX Models (huPDX)

Humanized patient-derived xenograft models combine a patient-derived tumor with a host reconstituted with human immune components. They exist to address a structural limitation of conventional PDX: the severely immunodeficient hosts required for engraftment of human tissue have, by definition, no functional immune system, and therefore cannot support evaluation of any agent whose mechanism depends on human immune effector function.

Altogen Labs supports humanized PDX studies across reconstitution formats, with immune monitoring and tumor endpoints measured in the same protocol. The platform sits at the intersection of the patient-derived and humanized service lines, and is the appropriate choice where inter-patient variability in immunotherapy response is itself the object of study rather than a source of noise.

Reconstitution formats

Three principal formats are used, and the choice materially constrains study design.

Peripheral blood mononuclear cell reconstitution produces rapid human T-cell engraftment. The experimental window is bounded by xenogeneic graft-versus-host disease, which develops within weeks through human T-cell recognition of murine major histocompatibility complex. Hosts null for murine MHC class I and II partially mitigate this. These models are deficient in natural killer cells, B cells, and myeloid lineages despite robust T-cell engraftment, so they answer T-cell dependent questions and little else.

CD34-positive hematopoietic stem cell reconstitution produces multilineage human immunity over a period of several weeks to a few months. Study durations are substantially longer than with peripheral blood reconstitution, at the cost of lead time before a study can open. Conventional dendritic cells and tissue macrophages remain underrepresented.

Cytokine-transgenic hosts improve reconstitution of specific lineages through expression of human cytokines, and are selected where myeloid, natural killer, or tissue macrophage biology is central to the mechanism. No single configuration is universally superior; selection follows the immune lineage of interest and the intended study duration.

For help matching a mechanism to a reconstitution format, request a quote.

Autologous and HLA-matched designs

The highest fidelity configuration pairs tumor and immune compartments from the same donor, eliminating major histocompatibility mismatch between them. Published work in autologous humanized models has demonstrated generation of human innate and adaptive populations that infiltrate the tumor microenvironment, recapitulation of activation and exhaustion programs in CD8-positive T cells, and a pro-tumor myeloid signature whose inhibition abrogates enhanced tumor growth. Extension of the approach to melanoma has shown capture of inter-patient variability in response to checkpoint blockade and to engineered cytokines.

Applications

Humanized PDX supports evaluation of immune checkpoint inhibitors, bispecific T-cell engagers and CD3-targeting antibodies, CAR-T and other engineered cell therapies, cytokine and immune agonist biology, and immune-mediated resistance mechanisms.

Applied examples

Checkpoint response variability. Tumors from three donors are established in matched humanized hosts and treated with the same checkpoint inhibitor, with response compared across donors to establish whether variability tracks with a candidate biomarker.

Engager dose selection. A CD3-engaging bispecific is administered across a dose range, with tumor response and cytokine release measured in parallel to define a therapeutic index rather than a maximally effective dose.

Infiltration mechanism. Treated and control tumors are assessed by flow cytometry for intratumoral effector populations and by immunohistochemistry for their spatial distribution, distinguishing genuine tumor infiltration from accumulation at the margin.

Interpretive limitations

Three limitations should be stated at design stage rather than discovered at analysis. Several checkpoint antibodies have species-restricted cross-reactivity, so target expression and binding must be confirmed for the system in use. Dendritic cell function and antigen presentation remain incomplete in most humanized configurations. Tertiary lymphoid structures and fully functional germinal centers are rarely reconstituted. Inter-donor heterogeneity adds a variance component absent from conventional xenograft work, and is managed through donor selection, stratified randomization, and adequate cohort sizing rather than ignored.

Reconstitution standards and human material

Human cell source, conditioning regimen, host background, reconstitution efficiency verified by flow cytometry, and graft-versus-host disease monitoring are recorded consistent with established minimal information standards for humanized mice. Reconstitution thresholds are met before animals are randomized to treatment, so that treatment groups are comparable in immune status as well as tumor burden. Human cells are commercially obtained from suppliers maintaining donor eligibility documentation; no fetal tissue or other primary human tissue is used or offered. All procedures are conducted under active IACUC protocols, with graft-versus-host disease specific humane endpoints defined in addition to tumor burden endpoints. GLP standards are applied where a study is formally designated as GLP.

Send tumor type, mechanism, and required study duration, or request a quote.